Fintech
Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study
New York, New York–(Newsfile Corp. – May 25, 2021) – PCG Digital — The positive results keep rolling in for Lexaria (LEXX). They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.
Though new to NASDAQ, Lexaria Bioscience Corp. has been producing positive test results with their patented DehydraTECHTM bio-absorption technology since 2016. The process has been used in foods, beverages, oral supplements, tablets, and capsules.
The first iteration of the technology – “Original” DehydraTECH – increased absorption rates of cannabinoids and nicotine by up to 390%. In 2019, newer versions – DehydraTECHTM 2.0 – tested as high as 923% above industry standards. But now, test results from May of 2021 showed a CBD delivery rate that was up to 2,708% stronger than medium chain triglyceride (MCT) oils which have become industry standard.
Over the past few years, the CBD industry has been using coconut and/or other MCT oils as the most common way to deliver oral cannabinoids, primarily because they taste good. These recent study results may change a few minds about that. Lexaria has been proving their science is effective for half a decade now.
Strategic Initiatives for 2021 Show a Diverse Use Scenario for DehydraTECHTM
A revolutionary technology like DehydraTECHTM has a wide range of uses that goes beyond consumer CBD use. In November of 2020, Lexaria published a list of 2021 strategic initiatives that also targets hypertension treatment, nicotine delivery, and antiviral absorption.
The anti-hypertension drug market is estimated at over $30 billion. In 2021, DehydraTECHTM CBD is part of three human clinical studies (already started and fully funded) on the effects of CBD as a hypertension treatment option. The first study conducted in 2018 produced evidence of a 5% drop in blood pressure after a single 90mg dose.
On the nicotine front, Lexaria has issued a technology license to Altria Ventures Inc. and is in the midst of a formal R&D agreement with British American Tobacco, two of the five largest nicotine companies in the world. Early studies on DehydraTECHTM nicotine oral pouches show nicotine effectiveness in 1.5-4 minutes.
Viral diseases like HIV, Influenza, Ebola, and now COVID-19, have killed millions in just the past few years. With the higher absorption rate of DehydraTECHTM, antiviral drugs for these diseases, currently administered by injection, could potentially be delivered orally.
Lexaria Expands into India with New Patent Approval
Adding to its already impressive collection of patents in the US, EU, and Australia, Lexaria was just approved for a new patent in India for “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” It’s the 19th patent they’ve been granted.
The new patent covers a broad range of ingredients, including NSAIDS, nicotine, and cannabinoids. As the title suggests, it’s a beverage patent, but the allowed product formats cover everything from carbonated sodas to fruit juices, coffee and energy drinks, and oral medicines.
CBD-infused beverages, though not the most lucrative offering from Lexaria, are part of the $23.6 billion consumer CBD market. An established position in that sector has helped the company grow in other areas that could be worth significantly more to them going forward.
Licensing and White Label Opportunities for Prospective Partners
Lexaria is a biopharmaceutical company, not a retail chain store. Other companies license the technology to empower their own retail brands which are currently available in thousands of locations across the US. The company’s main goal is to increase the use of DehydraTECHTM through strategic partnerships. That includes drug companies and consumer packaged goods.
The absorption rate achieved in clinical studies is due to the ability that DehydraTECHTM has shown in delivering fat-soluble molecules through the gastrointestinal system by piggy-backing and improving upon known, natural human absorptive processes. It’s also been shown effective in transdermal applications, giving it even broader potential for topical use.
Companies with existing drugs, oral supplements, beverages, and pills can license this technology and effectively increase the potency and effectiveness of their product. Lexaria is working with several partners now who are doing this.
As an investment, Lexaria (LEXX) is up 27.14% in the past thirty days. The iShares NASDAQ Biotechnology ETF (IBB) is down 2.88% over that period. Nasdaq (NDAQ) itself only gained 3.35%, so Lexaria definitely “beat the market.” That’s a good sign for partners and investors.
Disclaimer
This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.
Contact: [email protected]
As we close out 2024, the fintech industry continues to deliver headlines that underscore its dynamism and innovation. From IPO aspirations to groundbreaking regulatory milestones, today’s updates highlight the transformative power of fintech partnerships, regulatory evolution, and disruptive technologies. Here’s what you need to know.
Chime’s Quiet Step Toward Public Markets
Chime, the U.S.-based financial technology startup best known for its digital banking services, has taken a significant step by filing confidential paperwork for an initial public offering (IPO). As one of the most valuable private fintechs in the U.S., Chime’s move could potentially signal a renewed appetite for fintech IPOs in a market that has been cautious following fluctuating valuations across the tech sector.
With a valuation that reportedly exceeded $25 billion in its last funding round, Chime’s IPO could set a new benchmark for the industry. Observers note that its strong customer base and revenue growth may make it an appealing choice for investors seeking to capitalize on the digital banking boom. However, the timing and success of the IPO will depend on broader market conditions and the regulatory landscape.
Source: Bloomberg
ZBD’s Pioneering Achievement: EU MiCA License Approval
ZBD, a fintech company specializing in Bitcoin Lightning network solutions, has made history by becoming the first to secure an EU MiCA (Markets in Crypto-Assets Regulation) license. This landmark approval by the Dutch regulator positions ZBD at the forefront of compliant crypto-fintech operations in Europe.
MiCA, which aims to harmonize the regulatory framework for crypto-assets across the EU, has been a focal point for industry players aiming to establish legitimacy and expand their offerings. ZBD’s achievement not only validates its operational rigor but also sets a precedent for other fintech firms navigating the evolving regulatory landscape.
Industry insiders view this as a strategic advantage for ZBD as it broadens its footprint in Europe. By leveraging its regulatory approval, the company can accelerate its product deployment and establish trust with institutional and retail users alike.
Source: Coindesk, PR Newswire
The Fintech-Credit Union Synergy: A Blueprint for Innovation
The convergence of fintechs and credit unions continues to reshape the financial services ecosystem. Collaborative initiatives, such as the one highlighted in the recent partnership between fintech innovators and credit unions, are proving to be a potent force in delivering tailored financial solutions.
This “dream team” approach allows credit unions to leverage fintech’s technological expertise while maintaining their community-focused ethos. Key areas of collaboration include digital payments, personalized financial management tools, and enhanced loan processing capabilities. These partnerships not only enhance member engagement but also enable credit unions to remain competitive in an increasingly digital-first financial environment.
Industry analysts emphasize that such collaborations underscore a broader trend of traditional financial institutions embracing fintech-driven solutions to bridge service gaps and foster innovation.
Source: PYMNTS
Tackling Student Loan Debt: A Fintech’s Mission
Student loan debt remains a pressing issue for millions of Americans, and a Rochester-based fintech aims to offer relief through its cloud-based platform. This innovative solution is designed to simplify loan management and provide borrowers with actionable insights to reduce their debt burden.
The platform’s features include repayment optimization tools, personalized financial education, and seamless integration with loan servicers. By addressing the complexities of student loan management, this fintech is empowering borrowers to make informed decisions and achieve financial stability.
As the student loan crisis continues to evolve, solutions like this highlight the critical role fintech can play in addressing systemic financial challenges while fostering financial literacy and inclusion.
Source: RBJ
Industry Implications and Takeaways
Today’s updates underscore several key themes shaping the fintech landscape:
- Regulatory Milestones: ZBD’s MiCA license approval exemplifies the importance of regulatory compliance in unlocking growth opportunities.
- Strategic Partnerships: The collaboration between fintechs and credit unions demonstrates the value of combining technological innovation with traditional financial models to drive customer-centric solutions.
- Market Opportunities: Chime’s IPO move reflects a potential revival in fintech public offerings, signaling confidence in the sector’s long-term prospects.
- Social Impact: Fintech’s ability to tackle systemic issues, such as student loan debt, showcases its role as a force for positive change.
The post Fintech Pulse: Your Daily Industry Brief (Chime, ZBD, MiCA) appeared first on News, Events, Advertising Options.
Leading global payments platform SPAYZ.io has confirmed it will be attending iFX EXPO Dubai 2025 on 14 to 16 January. Exhibiting at Stand 64 at Trade Centre Dubai, SPAYZ.io’s team of professionals will be on hand providing live demonstrations of its renowned payment services for payment providers. Attendees will also receive exclusive insight into SPAYZ.io’s plans for 2025 alongside early early access to its upcoming plans for the new year.
SPAYZ.io delivers a host of payment solutions that leverage the latest technological innovations and open access to the fastest growing emerging markets across Africa, Europe and Asia. Over the past year, there has been huge demand for its Open Banking and local payment method services, alongside bank transfers, mass payouts, online banking and e-wallets.
Yana Thakurta, Head of Business Development at SPAYZ.io commented: “We look forward to once again participating at iFX Dubai to expand our network of partners and clients. It’s a fantastic way to kick off the year, connecting with thousands of industry leaders from FOREX platforms to trading companies, and everything in between.
“Our key goal for iFX Dubai EXPO 2025 is to expand our portfolio of solutions and geographies. We’re using this as an opportunity to partner with like-minded entities who share our ambition to provide payment solutions that are truly global.”
Come meet SPAYZ.io’s team at the Trade Centre Dubai at Stand 64. You can also book a meeting slot with a member of a team.
The post SPAYZ.io prepares for iFX EXPO Dubai 2025 appeared first on News, Events, Advertising Options.
Airtm, the most connected digital dollar account in the world, is proud to announce the addition of two distinguished industry leaders to its Board of Directors: Rafael de la Vega, Global SVP of Partnerships at Auctane, and Shivani Siroya, CEO & Founder of Tala. These appointments reflect Airtm’s commitment to innovation and financial inclusion as the company enters its next phase of growth.
“We are thrilled to welcome Rafael and Shivani to Airtm’s Board of Directors,” said Ruben Galindo Steckel, Co-founder and CEO of Airtm. “Their unique perspectives and proven track records will be invaluable as we continue scaling our platform to empower individuals and businesses in emerging markets. Together, we’ll push the boundaries of financial inclusion and innovation to create a more connected and equitable global economy. Rafael and Shivani bring a wealth of experience and strategic insight that will strengthen Airtm’s mission to connect emerging economies with the global market.”
Rafael de la Vega, a seasoned leader in fintech global partnerships and technology innovation, is currently the Global SVP of Partnerships at Auctane. With a proven track record of delivering scalable, impactful solutions at the intersection of fintech, innovation, and commerce, Rafael’s expertise will be pivotal as Airtm continues to grow. “Airtm has built a platform that breaks down barriers and opens up opportunities for people in emerging economies to connect to global markets. I am excited to contribute to its growth and help further its mission of fostering financial inclusion on a global scale,” said Rafael.
Shivani Siroya, CEO and Founder of Tala, is a pioneer in financial technology, renowned for empowering underserved communities through access to credit and essential financial tools. Her leadership in leveraging data-driven innovation aligns seamlessly with Airtm’s vision of creating more equitable financial opportunities. “Empowering underserved communities has always been at the core of my work, and Airtm’s mission resonates deeply with me. I’m thrilled to join the Board and work alongside such a dynamic team to expand access to financial tools that truly make a difference in people’s lives,” said Shivani.
The post Airtm Enhances Its Board of Directors with Two Strategic Appointments appeared first on News, Events, Advertising Options.
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief (Revolut, Bestow, Advyzon, Tyme Group, Nubank)
-
Fintech5 days agoFintech Pulse: Your Daily Industry Brief (Chime, ZBD, MiCA)
-
Fintech PR4 days agoAccording to Tickmill survey, 3 in 10 Britons in economic difficulty: Purchasing power down 41% since 2004
-
Fintech5 days agoSPAYZ.io prepares for iFX EXPO Dubai 2025
-
Fintech5 days agoAirtm Enhances Its Board of Directors with Two Strategic Appointments
-
Fintech PR4 days agoPresident Emmerson Mnangagwa met this week with Zambia’s former Vice President and Special Envoy Enoch Kavindele to discuss SADC’s candidate for the AfDB
-
Fintech PR4 days agoStay Cyber Safe This Holiday Season: Heimdal’s Checklist for Business Security
-
Fintech PR6 days agoGan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)